US agency wants 2 months safety data before approving Covid-19 vaccine

Washington (AFP) – The US Food and Drug Administration made public its guidance for issuing emergency approval for a Covid-19 vaccine on Tuesday, making it clear it wants to see follow-up two months after trial volunteers have their second dose.That move would make it impossible for the Donald Trump’s administration to have a vaccine on the market before the November 3 election, something the president frequently says is on the cards.”Data from Phase 3 studies should include a median follow-up duration of at least two months after completion of the full vaccination regimen to help provide adeq…

Read More

HEDGE accordingly